ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On August 9, 2019, Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2019. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press release dated August 9, 2019, entitled “Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates”|
ABEONA THERAPEUTICS INC. Exhibit
EX-99.1 2 tv527192_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates Five patients with MPS IIIB treated in the Transpher B Study of ABO-102 gene therapy Positive interim MPS IIIA data showed preservation of neurocognitive development in youngest patients with robust and sustained improvement in clinically relevant biomarkers Planned initiation of Phase 3 VIITALTM study evaluating EB-101 in recessive dystrophic epidermolysis bullosa in Q4 Company to host investor conference call Monday,…
To view the full exhibit click
About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.